PMS-IC is governed, managed and operated by a consortium of partners from the NHS, universities and industry partners.

Our Consortium Partners

Our consortium partners are comprised of the four NHS Health Boards: Greater Glasgow and Clyde, Grampian, Tayside and Lothian. From academia: the Universities of Glasgow, Edinburgh, Dundee and Aberdeen and from industry: ThermoFisher Scientific and Aridhia Informatics Ltd.


Board Members

Our Board is composed of representatives from the Consortium, including representatives from NHS Scotland and the Universities of Glasgow, Edinburgh, Aberdeen and Dundee in Scotland.

David Bunton

Chair Precision Medicine Scotland and Chief Executive of Reprocell

Dr. David Bunton is CEO of REPROCELL Europe, a life sciences company based in Glasgow, UK, and a subsidiary of REPROCELL Inc. Having founded a human tissue assay service company (Biopta Ltd.) in 2002, Dr. Bunton later took over as the CEO of the conjoint REPROCELL Europe business after the acquisition of Biopta by REPROCELL.

Previously a Lecturer at Glasgow Caledonian University, David has numerous publications in physiology and pharmacology to his name and is a respected opinion leader in the use of human tissue for drug discovery. He chairs the Scottish Lifesciences Association’s special interest group in precision medicine, is a member of the NC3Rs/MHRA working party on human tissues in safety pharmacology and is an advocate for the wider global use of human cells and tissues in drug development.

Marian McNeil

CEO, Precision Medicine Scotland

Ms McNeil is the Chief Executive of Precision Medicine Scotland – Innovation Centre where she has worked for 3 years. She has developed a strong understanding of precision medicine, gained through a variety of exemplar projects (6 to date) which have been run at Precision Medicine Scotland.

Ms McNeil gained a M.Sc. in Stratified Medicine and Pharmacological Innovation at the University of Glasgow. Prior to that she developed her extensive business experience from various management level roles within the pharmaceutical industry where she worked for over 10 years, working mostly in the Oncology Divisions of AstraZeneca and Eli Lilly.

Professor Anna F Dominiczak OBE, MD, FRCP, FRSE, FMedSci

Regius Professor of Medicine, Vice-Principal and Head of College of Medical, Veterinary and Life Sciences, University of Glasgow

Professor Anna Dominiczak is Regius Professor of Medicine, Vice Principal and Head of College of Medical, Veterinary and Life Sciences. She is also an honorary consultant physician and non-executive member of the Greater Glasgow and Clyde NHS Board.

She held a British Heart Foundation Chair of Cardiovascular Medicine at the University of Glasgow between 1997 and 2010, as well as the directorship of the Cardiovascular Research Centre between 2000 and 2010. Her major research interests are in hypertension, cardiovascular genomics and systems medicine and her total research income in the last three years totals more than £30 million.

Dr Carol Clugston BSc (Hons), PhD, CMgr, FCMI, FLF

College Secretary, College of Medical, Veterinary & Life Sciences, University of Glasgow

Carol took up post of College Secretary to the College of Medical, Veterinary & Life Sciences in August 2010. The College Secretary is effectively the Chief Operating Officer of the College, and supports the Head of College in strategic planning.

Carol has managerial responsibility for all operational functions of the College, including line management responsibility for all of the administrative and support staff in the College (>300). In addition to this role, Carol has responsibility for clinical research governance in partnership with NHS Greater Glasgow & Clyde, including compliance with legislation relating to the conduct of clinical trials.

Jim Reid

Chairman & CEO of Sistemic Ltd

Jim has worked in the life sciences sector for the past 40 years, holding senior roles within a number of the sectors leading companies including Axis-Shield PLC, Chiron S.A, Hoffman la Roche and Trinity Biotech Inc.

Since 2000, he has managed ChimaeraBio, a specialist life sciences investment fund which he founded with Karen Reid and has been involved with a number of Scotland’s more successful life science companies including Haptogen (acquired by Wyeth), Qnostics (acquired by BBI plc) and D3 Technologies (acquired by Renishaw plc). Jim was also Chairman at Lumora on its very successful exit in 2015. He continues to be a Board Director of a number of Life Science companies, the Scottish Life Science Association and the Mercia Fund Investment Board.

David Stirling

Director of Healthcare Science, NHS NSS

Director of Healthcare ScienceNHS National Services ScotlandHaving trained in Reproductive Biology, David Stirling spent some time working in Texas before joining the Imperial Cancer Research Fund in Edinburgh. He then joined NHS Lothian in 1991 as a Clinical Scientist in Haematology.

From 2011 to 2013 he took up a part time secondment to Scottish Government as Healthcare Science Officer, and in 2014 joined NHS NSS as Director of Healthcare Science.

Professor Colin Palmer

Associate Dean, Research & Chair of Pharmacogenomics at University of Dundee

Professor Colin Palmer is Associate Dean, Research & Chair of Pharmacogenomics at the School of Medicine. His laboratory specializes in population genetic research and has research projects studying the genetic basis for susceptibility to common diseases such as type 2 diabetes, heart disease, asthma and cancer

Current studies involve using the electronic medical register to link patient outcome to genomic information, including GWAS and next generation sequencing data. This will provide new drug targets for the prevention and treatment of such diseases and will also allow for more informed and personalised usage of current therapies.

Dr. David Sibbald OBE, FRSE

Chair PrecisionExecutive Chairman of Aridhia Informatics

David is the Co-Founder, Executive Chairman of Aridhia, a company dedicated to the application of health and biomedical informatics to improve the management of chronic disease and inform the delivery of Precision Medicine. He leads a multidisciplinary team of clinicians, computing scientists, data scientists and business specialists who together provide a unique combination of expertise to help address one of the world’s most pressing health problems.

Conflict of Interest Statement.

Prior to founding Aridhia, David was the Co-Founder, Chairman and CEO of Atlantech Technologies, a communications software company that was sold to Cisco Systems in March 2000.David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world. He is also the Founder and Chairman of the Johari Foundation and is a Vice-President of UNICEF UK, the United Nations children’s fund.David holds honorary doctorates from Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland’s National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.

Claire Wallace

Vice President of Sales, Thermo Fisher Scientific

Derek Marchant

Head of Finance, MVLS, University of Glasgow

Professor Moira Whyte

Head of College of Medicine and Veterinary Medicine / Sir John Crofton Professor of Respiratory Medicine

Professor Moira Whyte is the Sir John Crofton Professor of Respiratory Medicine and was formerly Director of the MRC/University of Edinburgh Centre for Inflammation Research and Head of Edinburgh Medical School. Since 1st April 2018 she has been Vice-Principal and Head of the College of Medicine and Veterinary Medicine.

A respiratory physician who trained mainly in London (St Bartholomew's Hospital Medical College, Hammersmith Hospital, Royal Postgraduate Medical School and Imperial Cancer Research Fund), after MRC and then Wellcome Clinical Fellowships, Moira was appointed Professor of Respiratory Medicine and subsequently Sir George Franklin Professor of Medicine at the University of Sheffield. She moved to Edinburgh in 2014.Her research interests have focused on molecular mechanisms underlying acute inflammation in the context both of chronic inflammatory lung diseases such as COPD and of host defence against bacterial infection.

Board Observers

Robin Lee

Senior Policy/Analysis Officer, Scottish Funding Council

Andrew Howie

Scottish Enterprise

Alan McNair

Chief Scientists Office, Scotland